After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom

After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom

Submitted by CP Staff on June 18, 2018 - 10:00am
Source: 
Endpoints
News Tags: 
Cytokinetics
clinical trials
reldesemtiv
Tirasemtiv
spinal muscular atrophy
Astellas
Headline: 
After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom
snippet: 

For the past 6 months, Cytokinetics $CYTK CEO Robert Blum has been holding things together in the wake of a devastating late-stage disaster that swept away its lead muscle drug. 

Do Not Allow Advertisers to Use My Personal information